Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.58 |
| ▸ | ESR1 | P03372 | 7/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25691438 | 0.92 | CRBN (0.49) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL29821907 | 0.91 | CRBN (0.57) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL23117863 | 0.91 | CRBN (0.57) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL23117862 | 0.91 | CRBN (0.57) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL30984796 | 0.90 | CRBN (0.64) | CRBNESR1IKZF2 | |
| SCHEMBL29597401 | 0.90 | CRBN (0.56) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL22645559 | 0.89 | CRBN (0.58) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL25691079 | 0.89 | CRBN (0.55) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL22645556 | 0.89 | CRBN (0.58) | CRBNESR1IKZF2DDB1IKZF3 | |
| SCHEMBL23134695 | 0.87 | CRBN (0.58) | CRBNESR1DDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021061642-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885ESR1 10/4885IKZF2 4315/4885 |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | CRBN 1098/4885ESR1 9/4885IKZF2 4069/4885 |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885ESR1 10/4885IKZF2 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.